<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03784703</url>
  </required_header>
  <id_info>
    <org_study_id>Statin Therapy</org_study_id>
    <nct_id>NCT03784703</nct_id>
  </id_info>
  <brief_title>Type 2 Diabetic Patients Maintained on Statin Therapy</brief_title>
  <official_title>Efficacy of Atorvastatin Versus Rosuvastatin on LV Function and Inflammatory Biomarkers in Type 2 Diabetic Patients With Dyslipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Damanhour University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Damanhour University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with diabetes mellitus (DM) are at increased risk of atherosclerotic cardiovascular&#xD;
      disease (ACVD). The achievement of the LDL-C target with statins for the reduction of ACVD&#xD;
      risk is recommended. However, the risk is still present. Therefore, we investigated the&#xD;
      impact of high sensitivity C-reactive protein (hsCRP), sortilin, adiponectin and leptin&#xD;
      biomarkers that linking inflammatory hypothesis of diabetes mellitus and atherosclerosis in&#xD;
      diabetic patients treated with rosuvastatin and atrovastatin. Methods: Based on exclusion&#xD;
      criteria, 150 type 2 diabetic patients were eligible and randomly assigned to receive either&#xD;
      40 mg per day atorvastatin (ATROVA group, n= 80) or 10 mg per day rosuvastatin (ROSUVA group,&#xD;
      n= 80) for 6 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      a prospective, double blind trial, conducted between January 2018 and January 2020.&#xD;
      Participants were enrolled if they had moderate cardiovascular risk (Framingham risk score of&#xD;
      10-20%), in other words 2 or more major risk factors for coronary artery disease (CAD), and&#xD;
      LDL-cholesterol level ≥100 mg/dl. All patients gave informed consent before entering the&#xD;
      study. Of 150 patients were randomly assigned to receive either 40 mg per day atorvastatin&#xD;
      tablets (ATROVA group, n= 80) or 10 mg per day Rosuvastatin (Rosuvastatin Calcium®,&#xD;
      Chemipharm Co. Cairo, Egypt) tablets (ROSUVA group, n= 80) as recommended in NCEP ATP III&#xD;
      (21). Patients included in the study were maintained on oral hypoglycemic agents (OHA)&#xD;
      according to their treatment regimen. Clinical and biochemical assessment was done at&#xD;
      baseline and after 6 months. Serum High-sensitivity CRP (hsCRP), sortilin, Adiponectin and&#xD;
      Leptin level was determined using ELISA Kit. Blood pressure (BP) and anthropometrical&#xD;
      parameters, such as body-mass index (BMI) were calculated using the equation (BMI = weight&#xD;
      (kg)/height (m2). Blood pressure was measured twice, after keeping participants in a sitting&#xD;
      position for 15 min. The mean value of two consecutive measurements with 5 min intervals was&#xD;
      used for study purposes. HbA1c% was determined by ion exchange method. Serum triglycerides&#xD;
      (TGs), total cholesterol (TCH), and high-density lipoprotein cholesterol (HDL-C) were&#xD;
      determined colorimetrically. Low-density lipoprotein-cholesterol (LDL-C) was calculated&#xD;
      according to Friedewald formula. Atherogenic Index (AI) is calculated through the following:&#xD;
      Atherogenic Index = TCH/HDL-C as TCH/HDL-C ratio is an excellent CVD risk predictor and a&#xD;
      good biomarker for deciding on the intensity and the need for therapeutic intervention.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Actual">January 31, 2020</completion_date>
  <primary_completion_date type="Actual">January 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>160 patients were randomly assigned to receive either 40 mg per day atorvastatin tablets (ATROVA group, n= 80) or 10 mg per day Rosuvastatin tablets (ROSUVA group, n= 80) as recommended in NCEP ATP III (21). Patients included in the study were maintained on oral hypoglycemic agents (OHA) according to their treatment regimen.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>prospective, double blind trial</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>hs-CRP (pg/mL)</measure>
    <time_frame>6 months</time_frame>
    <description>biomarkers that linking the inflammatory hypothesis with diabetes mellitus and atherosclerosis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>sortilin (ng/mL)</measure>
    <time_frame>6 months</time_frame>
    <description>Serum Level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>adiponectin (ng/mL)</measure>
    <time_frame>6 months</time_frame>
    <description>Serum Level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>leptin (ng/mL)</measure>
    <time_frame>6 months</time_frame>
    <description>Serum Level</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>glucose level</measure>
    <time_frame>6 months</time_frame>
    <description>fasting blood glucose (FBG) (mg/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glycated hemoglobin</measure>
    <time_frame>6 months</time_frame>
    <description>glycated hemoglobin (Hb A1c%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total cholesterol</measure>
    <time_frame>6 months</time_frame>
    <description>TCH: total cholesterol (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>low density lipoprotein-cholesterol</measure>
    <time_frame>6 months</time_frame>
    <description>LDL-C: low density lipoprotein-cholesterol (mg/dL), HDL-C: high density lipoprotein-cholesterol (mg/dL); Triglycerides (mg/dL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>high density lipoprotein-cholesterol</measure>
    <time_frame>6 months</time_frame>
    <description>HDL-C: high density lipoprotein-cholesterol (mg/dL); Triglycerides (mg/dL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>6 months</time_frame>
    <description>Triglycerides (mg/dL).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Dyslipidemia Associated With Type II Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Atrovastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>atorvastatin (40 mg per day) for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosuvastatin (10 mg per day) for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin 40 Mg Oral Tablet</intervention_name>
    <description>40 mg per day atorvastatin (ATROVA group, n= 80) for 6 months</description>
    <arm_group_label>Atrovastatin</arm_group_label>
    <other_name>Atorvastatin 40mg tablet per day</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin 10 Mg Oral Tablet</intervention_name>
    <description>10 mg per day rosuvastatin (ROSUVA group, n= 80) for 6 months</description>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <other_name>Resovastatin 10 mg daily</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  type II diabetic patients with hypercholesterolemia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  liver impairment,&#xD;
&#xD;
          -  renal insufficiency,&#xD;
&#xD;
          -  coronary artery disease,&#xD;
&#xD;
          -  metabolic disorders,&#xD;
&#xD;
          -  type I diabetes,&#xD;
&#xD;
          -  autoimmune diseases, cancer, infection,&#xD;
&#xD;
          -  use of anti-inflammatory drugs,&#xD;
&#xD;
          -  recent major surgery,&#xD;
&#xD;
          -  weight-loss or modified anti-hypertensive medications 12 weeks or less prior to&#xD;
             enrolment,&#xD;
&#xD;
          -  ongoing or previous use of lipid-lowering medications (including other statins, fibric&#xD;
             acid derivatives, nicotinic acid, cholestyramine, ezetimibe or omega-3 fatty acids)&#xD;
             and contraindications to the use of statins.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rehab Werida, Lecturer</last_name>
    <role>Study Director</role>
    <affiliation>Damanhour University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tanta University Hospital</name>
      <address>
        <city>Tanta</city>
        <state>El-Gharbia</state>
        <zip>31527</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <link>
    <url>https://onlinelibrary.wiley.com/doi/full/10.1111/1755-5922.12057</url>
    <description>The effect of simvastatin-ezetimibe combination therapy on adipose tissue hormones and systemic inflammation in patients with isolated hypercholesterolemia.</description>
  </link>
  <reference>
    <citation>Krysiak R, Zmuda W, Okopien B. The effect of simvastatin-ezetimibe combination therapy on adipose tissue hormones and systemic inflammation in patients with isolated hypercholesterolemia. Cardiovasc Ther. 2014 Apr;32(2):40-6. doi: 10.1111/1755-5922.12057.</citation>
    <PMID>24354929</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 13, 2018</study_first_submitted>
  <study_first_submitted_qc>December 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2018</study_first_posted>
  <last_update_submitted>December 30, 2020</last_update_submitted>
  <last_update_submitted_qc>December 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Damanhour University</investigator_affiliation>
    <investigator_full_name>Rehab Werida</investigator_full_name>
    <investigator_title>Clinical Pharmacy Lecturer</investigator_title>
  </responsible_party>
  <keyword>Adiponectin</keyword>
  <keyword>Sortilin</keyword>
  <keyword>Leptin</keyword>
  <keyword>Dyslipidemia</keyword>
  <keyword>Diabetes type II</keyword>
  <keyword>Rosuvastatin</keyword>
  <keyword>Atorvastatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

